Novo Nordisk | NVO - Cost Of Sales


Novo Nordisk reported DKK1.95B in Cost of Sales for its fiscal quarter ending in June of 2025.





Cost Of Sales Change Date
ANI Pharmaceuticals USD 114.5M 8.38M Mar/2026
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Bausch Health Companies USD 979M 55M Mar/2026
Bristol-Myers Squibb USD 3.86B 1.07B Mar/2026
Canopy Growth CAD 53.08M 8.3M Dec/2025
Corcept Therapeutics USD 2.88M 338K Mar/2026
Drreddys Laboratories INR 40.46B 3.64B Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Merck USD 2.94B 380M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Novartis USD 3.46B 83M Mar/2026
Novo Nordisk DKK 13.6B 1.55B Mar/2026
Novo Nordisk DKK 1.95B 10.94B Jun/2025
Pacira USD 50.74M 3.89M Mar/2026
Perrigo USD 643.7M 103.7M Mar/2026
Phibro Animal Health USD 240.42M 2.58M Dec/2025
Prestige Brands USD 140.76M 9.53M Mar/2026
Sanofi EUR 3.67B 621M Mar/2026
Supernus Pharmaceuticals USD 49.04M 1.5M Mar/2026
Zoetis USD 672M 71M Mar/2026